Pilgrimage And Pipeline: MERS Prospects
This article was originally published in Scrip
The renewed break-out of a frighteningly deadly virus with no known cure or vaccine in a region that will shortly host a couple of million international pilgrims has prompted a rash of recent headlines linking Middle East Respiratory Syndrome (MERS), the SARS-like coronavirus that first emerged in Saudi Arabia in 2012, and the annual Hajj to Mecca.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.